Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).

4071Background: Durvalumab, an anti-PD-L1 mAb, has shown early and durable clinical activity with manageable safety in an ongoing Phase 1/2, multicenter, open-label study in pts with advanced solid...